Mylan Releases "A Legacy of Impact: 2019 Global Social Responsibility Report"
Experience the interactive Multichannel News Release here: https://www.multivu.com/players/English/8094855-mylan-global-social-responsibility-gsr-report/
The report provides a comprehensive, enterprise-wide overview of Mylan's operations as they relate to environmental, social and governance (ESG) matters. More specifically, it includes an overview of the company's impact over the years on access to medicine, patients, employees, the environment, global public health and the community and highlights its most recent efforts and achievements in those areas.
The report's publication comes at a time when the world is united in the fight against the COVID-19 pandemic. Mylan's focus remains on the health and safety of its employees, while also working to ensure supply continuity as well as support patients and communities during this unprecedented time. The company will continue to provide regular updates on its efforts via its website.
"While the world around us has changed, Mylan's mission has remained the same for almost 60 years," said
In 2019 alone, Mylan demonstrated this commitment by:
- Delivering ~62 billion doses of medicine across more than 165 countries and territories, including ~90% of low- and lower-middle-income countries;
- Providing Mylan medication to ~60% of the world's HIV+ children receiving treatment;
- Growing our renewable energy consumption by 25%;
- Becoming the first generic manufacturer to receive WHO prequalification for a hepatitis C treatment; and
- Announcing a global partnership to increase access to tuberculosis treatments in many low-income countries.
"A fundamental component of Mylan's operations and overall focus is ensuring long-term, sustainable results and positive impact in everything we do," said
To learn more visit http://www.mylan.com/en/social-responsibility.
Commitment to the
Mylan is a signatory to the U.N. Global Compact and is committed to its 10 principles aimed at protecting human rights and the environment and ensuring fair labor and corruption-free business practices. The Global Social Responsibility 2019 Progress Report constitutes Mylan's Communication on Progress Report.
Support of the
Mylan is a global pharmaceutical company committed to setting new standards in healthcare. Working together around the world to provide 7 billion people access to high quality medicine, we innovate to satisfy unmet needs; make reliability and service excellence a habit; do what's right, not what's easy; and impact the future through passionate global leadership. We offer a portfolio of more than 7,500 marketed products around the world, including antiretroviral therapies on which approximately 40% of people being treated for HIV/AIDS globally depend. We market our products in more than 165 countries and territories. We are one of the world's largest producers of active pharmaceutical ingredients. Every member of our approximately 35,000-strong workforce is dedicated to creating better health for a better world, one person at a time. Learn more at Mylan.com. We routinely post information that may be important to investors on our website at investor.mylan.com.
This press release includes statements that constitute "forward-looking statements," including with regard to 2019 currently being expected to be Mylan's last year as a standalone company; the potential impact of COVID-19 and Mylan's role in continuing to help fight the battle against COVID-19; and Mylan's focus remaining on the health and safety of its employees, while also working to ensure supply continuity as well as support patients and communities during this unprecedented time. Because forward-looking statements inherently involve risks and uncertainties, actual future results may differ materially from those expressed or implied by such statements. Factors that could cause or contribute to such differences include, but are not limited to; the potential widespread and highly uncertain impact of public health outbreaks, epidemics and pandemics, such as the COVID-19 pandemic; any changes in, interruptions to, or difficulties with Mylan's or its partners' ability to develop, manufacture, and commercialize products; the effect of any changes in Mylan's or its partners' customer and supplier relationships and customer purchasing patterns; other changes in third-party relationships; the impact of competition; changes in the economic and financial conditions of the businesses of Mylan or its partners; the scope, timing, and outcome of any ongoing legal proceedings and the impact of any such proceedings on Mylan's or its partners' business; any regulatory, legal, or other impediments to Mylan's or its partners' ability to bring products to market; actions and decisions of healthcare and pharmaceutical regulators, and changes in healthcare and pharmaceutical laws and regulations, in
Christine Waller (Media), 724.514.1968 or Melissa Trombetta (Investors), 724.514.1813